1. Home
  2. AMPL vs SNDX Comparison

AMPL vs SNDX Comparison

Compare AMPL & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amplitude Inc.

AMPL

Amplitude Inc.

HOLD

Current Price

$11.27

Market Cap

1.7B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.29

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMPL
SNDX
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
AMPL
SNDX
Price
$11.27
$20.29
Analyst Decision
Buy
Strong Buy
Analyst Count
11
12
Target Price
$14.45
$36.92
AVG Volume (30 Days)
1.0M
2.1M
Earning Date
11-05-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$329,919,000.00
$111,304,000.00
Revenue This Year
$16.63
$620.14
Revenue Next Year
$14.17
$115.42
P/E Ratio
N/A
N/A
Revenue Growth
12.78
595.65
52 Week Low
$7.55
$8.58
52 Week High
$14.88
$21.22

Technical Indicators

Market Signals
Indicator
AMPL
SNDX
Relative Strength Index (RSI) 64.46 64.85
Support Level $11.03 $19.11
Resistance Level $11.71 $21.22
Average True Range (ATR) 0.34 1.02
MACD 0.11 0.02
Stochastic Oscillator 76.84 73.54

Price Performance

Historical Comparison
AMPL
SNDX

About AMPL Amplitude Inc.

Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: